{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-26-000049","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2026-05-27T20:07:11+00:00","discovered_at":"2026-05-27T20:08:00.526322+00:00","generated_at":"2026-05-27T20:11:26.806584+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Zentalis appoints Shannon Campbell as Class I director, expanding board to 7 members","bullets":["Board increased from 6 to 7 directors; Campbell appointed as Class I director effective May 22, 2026.","Annual retainer of $45,000 for board service plus $7,500 for Compensation Committee membership.","Granted RSUs covering 114,200 shares on May 26, 2026, vesting one-third annually over three years.","After 6 months, eligible for annual equity grant of RSUs covering 0.08% of outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-26-000049","json":"https://secwatch.observer/filing/0001725160-26-000049.json","markdown":"https://secwatch.observer/filing/0001725160-26-000049.md","text":"https://secwatch.observer/filing/0001725160-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/zntl-20260522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T20:11:26.806584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9642ea7149","claim":"Shannon Campbell was appointed as Director at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001477932-26-003559","ticker":"JOB","company_name":"GEE Group Inc.","filed_at":"2026-06-01T20:47:44+00:00","headline":"Darla Moore resigns from GEE Group board effective June 1, 2026, due to other commitments","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003559","json":"https://secwatch.observer/filing/0001477932-26-003559.json","markdown":"https://secwatch.observer/filing/0001477932-26-003559.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/0001477932-26-003559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/job_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","comparable_excerpt":"On June 1, 2026, GEE Group Inc. (the “Company”) (NYSE American: JOB) issued a press release announcing that Ms. Darla Moore, has resigned as a member of the Board of Directors (the “Board”) and from all committees of the Company’s Board effective June 1, 2026, due to the time requirements necessary for her existing and new business commitments.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/0001477932-26-003559-index.htm"}},{"accession":"0001534969-26-000028","ticker":"SERA","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2026-06-01T20:44:21+00:00","headline":"Sera Prognostics director Jeff Elliott resigns ahead of annual meeting","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-26-000028","json":"https://secwatch.observer/filing/0001534969-26-000028.json","markdown":"https://secwatch.observer/filing/0001534969-26-000028.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/0001534969-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/sera-20260526.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","comparable_excerpt":"Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/0001534969-26-000028-index.htm"}},{"accession":"0001681459-26-000035","ticker":"FTI","company_name":"TechnipFMC plc","filed_at":"2026-06-01T20:38:05+00:00","headline":"TechnipFMC appoints Eric D. Mullins to Board of Directors effective June 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001681459-26-000035","json":"https://secwatch.observer/filing/0001681459-26-000035.json","markdown":"https://secwatch.observer/filing/0001681459-26-000035.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681459/000168145926000035/0001681459-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681459/000168145926000035/fti-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","comparable_excerpt":"the Board elected Eric Mullins to the Board and appointed Mr. Mullins to the Audit Committee of the Board, effective June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1681459/000168145926000035/0001681459-26-000035-index.htm"}},{"accession":"0001193125-26-251548","ticker":"MCRB","company_name":"Seres Therapeutics, Inc.","filed_at":"2026-06-01T20:30:55+00:00","headline":"Seres Therapeutics board member Hans-Juergen Woerle resigns, effective May 31, 2026","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251548","json":"https://secwatch.observer/filing/0001193125-26-251548.json","markdown":"https://secwatch.observer/filing/0001193125-26-251548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526251548/0001193125-26-251548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526251548/d100982d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","comparable_excerpt":"On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526251548/0001193125-26-251548-index.htm"}},{"accession":"0000827054-26-000020","ticker":"MCHP","company_name":"MICROCHIP TECHNOLOGY INC","filed_at":"2026-06-01T20:18:43+00:00","headline":"Microchip appoints former SVP Mitch Little to board, effective June 1, 2026","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000827054-26-000020","json":"https://secwatch.observer/filing/0000827054-26-000020.json","markdown":"https://secwatch.observer/filing/0000827054-26-000020.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/827054/000082705426000020/0000827054-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/827054/000082705426000020/mchp-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","comparable_excerpt":"appointed Mitch Little, former Senior Vice President, Worldwide Client Engagement of Microchip, as a member of the Board, effective June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/827054/000082705426000020/0000827054-26-000020-index.htm"}},{"accession":"0001680247-26-000091","ticker":"PUMP","company_name":"ProPetro Holding Corp.","filed_at":"2026-06-01T20:16:36+00:00","headline":"Director Alex Volkov resigns from ProPetro board after Pioneer (Exxon) sells all shares","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001680247-26-000091","json":"https://secwatch.observer/filing/0001680247-26-000091.json","markdown":"https://secwatch.observer/filing/0001680247-26-000091.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680247/000168024726000091/0001680247-26-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680247/000168024726000091/pump-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","comparable_excerpt":"On May 28, 2026, ProPetro Holding Corp. (the “Company”) announced the resignation of Alex V. Volkov from the Company’s Board of Directors (the “Board”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1680247/000168024726000091/0001680247-26-000091-index.htm"}},{"accession":"0001104659-26-068930","ticker":"DE","company_name":"DEERE & CO","filed_at":"2026-06-01T20:15:26+00:00","headline":"Deere director Dmitri Stockton will not seek re-election at 2027 annual meeting","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068930","json":"https://secwatch.observer/filing/0001104659-26-068930.json","markdown":"https://secwatch.observer/filing/0001104659-26-068930.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/315189/000110465926068930/0001104659-26-068930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315189/000110465926068930/de-20260526x8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","comparable_excerpt":"On May 26, 2026, Dmitri Stockton notified the Board of Directors (the “Board”) of Deere & Company (the “Company”) that he would not stand for re-election as a director at the 2027 annual meeting of stockholders.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/315189/000110465926068930/0001104659-26-068930-index.htm"}},{"accession":"0000067215-26-000028","ticker":"DY","company_name":"DYCOM INDUSTRIES INC","filed_at":"2026-06-01T12:04:32+00:00","headline":"Dycom board reduced to nine; two directors retire after annual meeting","event_type":"leadership","sec_items":["5.02","5.07"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000067215-26-000028","json":"https://secwatch.observer/filing/0000067215-26-000028.json","markdown":"https://secwatch.observer/filing/0000067215-26-000028.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/67215/000006721526000028/0000067215-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/67215/000006721526000028/dy-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm","comparable_excerpt":"Ms. Laurie J. Thomsen did not stand for election at the 2026 Annual Meeting of Shareholders held on May 28, 2026 (the “2026 Annual Meeting”) and retired from the Board effective at the conclusion of the 2026 Annual Meeting.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/67215/000006721526000028/0000067215-26-000028-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}